News and Investors
Listen to Mike Mangano, president and CEO discussing the strides ABK Biomedical is taking to advance the treatment of liver cancer
Latest News
November 19th 2024
ABK Biomedical Announces FDA IDE Stage 2 Approval for Route90, a Prospective, Multi-Center, Pivotal Study of Eye90 Microspheres® in Unresectable Hepatocellular Cancer
Go to the Press Release»»
December 5th 2023
ABK Biomedical Announces that its Eye90 microspheres® device has been granted Breakthrough Device Designation by the U.S. Food and Drug Administration (FDA)
Go to the Press Release»»
October 24th 2023
ABK Biomedical Announces First Patient Treated in its Multi-Center Pivotal Study of Eye90 microspheres® in Hepatocellular Carcinoma
Go to the Press Release»»
May 30th 2023
ABK Biomedical Announces FDA IDE Approval for a Multi-Center Pivotal Study of Eye90 microspheres® in Hepatocellular Carcinoma
Go to the Press Release»»
December 6th 2022
ABK Biomedical Raises USD 30M in Series C Funding
Go to the Press Release»»
September 12th 2022
ABK Biomedical announces FDA 510(k) clearance of Easi-Vue™ embolic microspheres for the embolization of arteriovenous malformations and hypervascular tumors
Go to the Press Release»»
September 12th 2022
ABK Biomedical announces the appointment of Dr. Aravind Arepally as Chief Medical Officer effective, September 12th 2022
Read More»»
Company News & Press Releases
ABK Biomedical Announces FDA IDE Approval for a Multi-Center Pivotal Study of Eye90 microspheres® in Hepatocellular Carcinoma
Halifax, Nova Scotia. May 30th, 2023. ABK Biomedical an innovative medical device company dedicated to the research, development, and commercialization of advanced imageable embolic therapies…
Read the Press Release»»
ABK Biomedical Raises USD 30M in Series C Financing
Halifax, Nova Scotia. December 6th 2022. ABK Biomedical an innovative medical device company dedicated to the research, development, and commercialization of advanced imageable embolic therapies…
Read the Press Release»»
ABK Biomedical announces FDA 510(k) clearance of Easi-Vue™ embolic microspheres for the embolization of arteriovenous malformations and hypervascular tumors
Halifax, Nova Scotia. September 12th 2022. ABK Biomedical, an innovative medical device company dedicated to the research…
Read the Press Release»»
ABK Biomedical Announces First Patient Treated in First-in-Human Clinical Study with Eye90 microspheres™ for treatment of liver tumors
Halifax, Nova Scotia. April 19th, 2022. ABK Biomedical, Inc, an innovative, clinical-stage medical device company dedicated to the research…
Read the Press Release»»
In The News
Podcast on Eye90 microspheres® on ResearchPod
Listen to ABK Biomedical’s Chief Medical Officer Aravind Arepally, M.D. and E. Courtney Henry, PhD, Medical Physics discuss Eye90 microspheres for the treatment of unresectable liver cancer on ResearchPod by clicking here.
Abstract on Eye90 Microspheres Precision Dosimetry™ wins Best Abstract award, profiled in Oncology Business Review September 2023
ABK Biomedical and associated researchers recently won the “Best Abstract” award at the Symposium on Clinical Interventional Oncology in Orlando, September 2023.
This recognition for our ongoing advancement of Y90 research came from a presentation around our First-in-Human New Zealand HCC study and was profiled in Oncology Business Review. Click here to read the OBR article or here to download the poster.
Easi-Vue™ embolic microspheres featured in Design News September 2022
Design News recently profiled the important 510(k) clearance for Easi-Vue embolic microspheres.
Chief Business Officer, Gary Donofrio, and VP of manufacturing Anthony Headley provided ABK Biomedical’s perspective on the importance of this achievement, and on the impact this see-and-do technology may have on patient treatment practices.
Click here to read the article.
Eye90 microspheres Precision Dosimetry™ profiled in Physics World July 2022
MD Anderson Cancer Center post-doctoral fellow and ABK-affiliated researcher Dr. E Courtney Henry presented on recent advances in Y90 dosimetry at the 2022 American Association of Physicists in Medicine annual meeting.
The association recognized this research as a “Best in Physics” presentation. Click here to read more about this important advance and its impact on Y90 technology.
ABK Chief Medical Officer interviewed by Interventional News
Bob Abraham, MD, CMO at ABK Biomedical was interviewed by Interventional News in 2020 at The SPECTRUM Conference. Dr Abraham discussed the potential of using CT imaging with ABK Biomedical’s radiopaque microspheres to precisely map absorbed radiation dose.
Click the image for Dr Abraham’s perspective on this exciting advance in microsphere technology.
Co-Founder Discusses ABK’s Unique Microsphere Technology
ABK Biomedical Co-founder, Dr. Daniel Boyd, outlines the history of ABK, and the novel glass microsphere technologies the company is developing.
Business Partners
ABK Biomedical is proud to partner with cutting-edge organizations and individuals with exceptional skills, scientific expertise, and the highest business ethics.
Research Partners
Development Partners
ABK Biomedical is ISO Certified
The ABK Biomedical Team
We are dedicated to encouraging a stimulating work environment offering an opportunity to significantly expand experience and skills by researching, developing, and commercializing cutting-edge medical device technologies with a mandate to effectively treat cancer.
ABK Biomedical is an equal opportunity employer offering competitive compensation packages.
Corporate Offices
Halifax Office (Main Office)
155 Chain Lake Drive
Unit 32
Halifax, NS B3S 1B3
Canada
T. 902.442.4009
Orange County Office
555 Corporate Drive
Suite 105
Ladera Ranch, CA, 92694
USA
ABK Biomedical Inc. provides and continues to provide accurate information on its website. However, ABK Biomedical Inc. assumes no responsibility for the accuracy and/or completeness, express or implied, as to the information contained or omitted and/or the products described. Furthermore, ABK Biomedical Inc. may change the products mentioned, and their stage in development, at any time without notice. ABK Biomedical Inc. is a clinical-stage company engaged in the research and development of new medical devices. Eye90 microspheres® is considered an investigational product and is NOT FDA-approved for use.
Copyright 2022 - All International Rights Reserved